Ans. is d i.e. Prophylactic oophorectomy BRCA-1 and BRCA-2 are tumour suppressor genes. BRCA-1 is located on chromosome 17 and BRCA-2 on chromosome 13. Individuals who inherit mutations of BRCA-1 and BRCA-2 are highly susceptible for the development of hereditary breast or ovarian cancer. The mutations are inherited as autosomal dominant. Lifetime risk of Ovarian Ca in individual with these mutation - 25% Lifetime risk of Breast Ca in individual with these mutation - 50% BRCA-1 - (20-40% life time risk of ovarian cancer). BRCA-2 - (10-20% life time risk of ovarian cancer). Men in these families have an increased risk of prostate cancer. Strategies for prevention of hereditary ovarian cancer Genetic testing for susceptibility to ovarian cancer is rapidly becoming integrated into the clinical practice of oncology. Strategies have been adopted to reduce the incidence of ovarian cancer in patient with BRCA-1 and BRCA-2 mutations. Prophylactic oophorectomy : "The only proven way to prevent ovarian cancer is surgical oopherectomy. As another possible site of disease among these high risk patients is fallopian tube therefore should be removed. IN BRCA 1 or BRCA-2 mutation carriers, prophylactic bilateral salpingo-oophorectomy (B50) may be performed on either completion of childbearing or at age 35. In these patients, the procedure is approximately 90% effective in preventing epithelial ovarian cancer. In women with HNPCC, the risk reduction approaches 100%." Additional benefit of prophylactic oopherectomy is that the risk of breast cancer is reduced by 50-80%. Oral contraceptive pills : Data received from a multicenter control of genetic screening centers indicates that the use of oralcontraceptive pill is associated with 50% decreased risk for developing ovarian cancer in women who have mutation in either in BRCA - 1 or BRCA - 2. However there is sho term increased risk of developing breastcancer. Role of screening with CA 125 and transvaginal ultrasound : "In BRCA1- BRCA2 mutation carriers who donot wish to undergo prophylactic surgery a combination of through pelvic examination, transvaginal sonographic examination and CA 125 blood testing should be done". Oral contraceptive pills : Data received from a multicenter control of genetic screening centers indicates that the use of oral contraceptive pill is associated with 50% decreased risk for developing ovarian cancer in women who have mutation in either in BRCA - 1 or BRCA - 2. However there is sho term increased risk of developing breast cancer. Role of screening with CA 125 and transvaginal ultrasound : "In BRCA1- BRCA2 mutation carriers who donot wish to undergo prophylactic surgery a combination of through pelvic examination, transvaginal sonographic examination and CA 125 blood testing should be done".